论文部分内容阅读
用ＣＤ３ＭｃＡｂ和低剂量ＩＬ－２（５００Ｕ／ｍｌ）诱导的人胎脾ＣＤ３ＡＫ细胞治疗４３例晚期恶性肿瘤患者，取得疗效。经２～８疗程治疗，多数患者症状缓解，生活质量改善，ＰＲ＋ＭＲ１８例（４１．９％），Ｓ＋Ｐ２５例（５８．１％），死亡９例（２０．９％）。全组无严重毒副反应发生。同时比较ＣＤ３ＡＫ细胞和常规ＬＡＫ细胞体外增殖及其杀伤活性，表明前者１４４ｈ增殖力高于后者（Ｐ＜０．０１），靶细胞抑制率二者无显著差异（Ｐ＞０．０５）。初步表明ＣＤ３ＡＫ／ＩＬ－２疗法效果肯定，毒副作用小，可能成为继ＬＡＫ／ＩＬ－２之后更为有效的肿瘤辅助治疗。
Human fetal spleen CD3AK cells induced by CD3 McAb and low dose of IL-2 (500 U/ml) were used to treat 43 patients with advanced malignant tumors and achieved curative effect. After 2 to 8 courses of treatment, the majority of patients experienced symptom relief and improved quality of life. PR+MR was found in 18 cases (41.9%), S+P in 25 cases (58.1%), and death in 9 cases (20.9%). No serious side effects occurred in the whole group. At the same time, the proliferation and killing activity of CD3AK cells and conventional LAK cells were compared in vitro, indicating that the proliferation of the former was higher than that of the latter (P<0.01), and there was no significant difference in the inhibitory rate of target cells (P>0.05). It has been initially demonstrated that CD3AK/IL-2 therapy is effective, with little side effects, and may become a more effective tumor adjuvant therapy following LAK/IL-2.